Your browser doesn't support javascript.
loading
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study.
Lo Caputo, Sergio; Poliseno, Mariacristina; Tavelli, Alessandro; Gagliardini, Roberta; Rusconi, Stefano; Lapadula, Giuseppe; Antinori, Andrea; Francisci, Daniela; Sarmati, Loredana; Gori, Andrea; Spagnuolo, Vincenzo; Ceccherini-Silberstein, Francesca; d'Arminio Monforte, Antonella; Cozzi-Lepri, Alessandro.
Afiliação
  • Lo Caputo S; Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy.
  • Poliseno M; Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Jonian Area (DiMePreJ), A.O.U.C. Policlinic di Bari, Bari, Italy. Electronic address: polisenomc@gmail.com.
  • Tavelli A; ICONA Foundation, Milan, Italy.
  • Gagliardini R; HIV/AIDS Department, INMI L. Spallanzani IRCC, Rome, Italy.
  • Rusconi S; Infectious Diseases Unit, ASST Ovest Milanese Ospedaledi Legnano, and DIBIC, University Milan, Legnano, Italy.
  • Lapadula G; IRCCS Fondazione San Gerardo dei Tintori, University of Milano Bicocca, Milan, Italy.
  • Antinori A; HIV/AIDS Department, INMI L. Spallanzani IRCC, Rome, Italy.
  • Francisci D; Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy.
  • Sarmati L; Department of System Medicine, Infectious Disease Clinic, Policlinic Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
  • Gori A; Department of Pathophysiology and Transplantation, Infectious Diseases Unit, Foundation IRCCS Ca' GrandaOspedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Spagnuolo V; Unit of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy.
  • Ceccherini-Silberstein F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
  • d'Arminio Monforte A; Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
  • Cozzi-Lepri A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, UCL London, United Kingdom.
Int J Infect Dis ; 143: 106956, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38447754
ABSTRACT

OBJECTIVES:

Heavily treatment-experienced (HTE) people living with HIV (PLWH) pose unique challenges due to limited antiretroviral treatment (ART) options. Our study aimed to investigate the prevalence and features of HTE individuals followed up in the Italian Cohort Naïve Antiretrovirals (ICONA) cohort as of December 31, 2021.

METHODS:

HTE were defined based on meeting specific conditions concerning their current ART and their ART history up to December 31, 2021. Descriptive statistics were performed by HTE status. Regression analyses explored factors associated with becoming HTE based on pre-ART patients' characteristics. Cluster dendrogram analysis provided insights into subgroups with inadequate responses based on clusters of differentiation (CD4) counts and viral load (VL) trajectories.

RESULTS:

Among the 8758 PLWH actively followed in our cohort, 163 individuals (1.9%), mainly female, younger, Italian, and infected through heterosexual contact, met the HTE criteria. A lower CD4 count at ART initiation (odds ratio [OR] 1.60 per 100 cells/mmc lower CD4, 95% confidence interval [CI] 1.06-2.41, P = 0.03) and hepatitis C virus antibody positivity (OR 1.90, 95% CI 1.16-3.11, P = 0.01) were associated with higher HTE risk. Thirty PLWH exhibited ongoing immune-virological failure (18% of the HTE subgroup and 0.003% of the total population). Thirty PLWH exhibited ongoing immune-virological failure (i.e., with a current CD4 count <200 cells/mmc or VL>200 copies/mL). A cluster analysis identified 13 (43%) with a current CD4 count <200 cells/mmc. Also, notably, 19/30 (63%) had major acquired resistance-associated mutations to at least one antiretroviral drug class.

CONCLUSIONS:

HTE is rare in our cohort and tends to co-exist with major resistance mutations. A focused investigation into treatment history and immuno-virological response is warranted, particularly given the availability of new antiretroviral drugs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Carga Viral Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Infect Dis Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Carga Viral Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Infect Dis Ano de publicação: 2024 Tipo de documento: Article